Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDS [0.03%]
双剂量克拉屈滨和氟达拉滨与两种分次方案的髓核消减剂布舒芬联合治疗AML或MDS的随机临床试验
Uday R Popat,Konstantinos Lontos,Roland Bassett et al.
Uday R Popat et al.
Background: A myeloablative busulfan and fludarabine regimen that includes fractionating busulfan and extending its delivery time results in low toxicity, permitting its use in stem cell transplant recipients who would ot...
Impact of Bridging Response on Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma [0.03%]
CD19-CAR修饰的T细胞治疗大B细胞淋巴瘤后桥接反应对预后的的影响
Beatriz Wills,Sarah Samorodnitsky,Samantha Brown et al.
Beatriz Wills et al.
Background: Bridging therapy (BT) is frequently administered during CD19 CAR T-cell manufacturing for relapsed or refractory large B-cell lymphoma (LBCL), and although disease status at infusion has been associated with o...
Impact of Acute Graft-Versus-Host Disease and Delayed Hematopoietic Recovery on the Incidence and Clinical Burden of Late Cytomegalovirus Reactivation and Disease After Letermovir Prophylaxis During the First 100 Days After Cord Blood Transplantation [0.03%]
移植物抗宿主病和造血恢复延迟对胎盘血移植后前100天使用雷特姆韦预防期间晚期巨细胞病毒再活化和疾病的发生率和临床负担的影响
Naoki Okada,Hiroyuki Muranushi,Junya Kanda et al.
Naoki Okada et al.
Background: Cord blood transplantation (CBT) is associated with a particularly high risk of cytomegalovirus (CMV) complications due to delayed immune reconstitution. While letermovir (LTV) prophylaxis is effective in the ...
Neighborhood socioeconomic disadvantage and distance from treatment center do not impact survival outcomes of patients with non-Hodgkin lymphoma and multiple myeloma treated with CAR T-cell therapies [0.03%]
CAR-T治疗非霍奇金淋巴瘤和多发性骨髓瘤患者的预后与居住地经济社会劣势及往返治疗中心的距离无关
Agrima Mian,Rafaella Litvin,Danai Dima et al.
Agrima Mian et al.
Background: Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment of relapsed/refractory (r/r) hematologic malignancies but are largely delivered at specialized academic centers. Socioeconomic an...
Polyomavirus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Multicenter Retrospective Analysis [0.03%]
多中心回顾性分析进行性多灶性白质脑病中的多瘤病毒特异性T细胞
Alexandre Chevalier,Baptiste Bonneau,Lea Grote-Levi et al.
Alexandre Chevalier et al.
Background: Progressive multifocal leukoencephalopathy (PML) is a rare brain infection caused by JC polyomavirus (JCPyV) in immunocompromised individuals, for which no effective antiviral therapy exists. Diverse cellular ...
Search Prognosis Driven Transplantation: A New Paradigm for Donor Selection in Allogeneic HCT [0.03%]
基于预后的搜索移植供者：异基因造血干细胞移植供者选择的新范例
Mahmoud Aljurf,Abdelghani Tbakhi
Mahmoud Aljurf
Keith M Sullivan,Stephen J Forman
Keith M Sullivan
Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression [0.03%]
单特异性和双特异性嵌合抗原受体(CAR)T细胞治疗多发性骨髓瘤的系统评价、荟萃分析和荟萃回归分析
Ainsley Ryan Yan Bin Lee,Hon Jen Wong,Chi Ching Lim et al.
Ainsley Ryan Yan Bin Lee et al.
Background: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for relapsed/refractory multiple myeloma (RRMM). However, comparative effectiveness across CAR products, target antigens, and patient...